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Background: Hereditary hearing loss is one of the most common heterogeneous disorders, and genetic variants
that can cause hearing loss have been identified in over sixty genes. Most of these hearing loss genes have been
detected using classical genetic methods, typically starting with linkage analysis in large families with hereditary
hearing loss. However, these classical strategies are not well suited for mutation analysis in smaller families who
have insufficient genetic information.
Methods: Eighty known hearing loss genes were selected and simultaneously sequenced by targeted next-generation
sequencing (NGS) in 8 Korean families with autosomal dominant non-syndromic sensorineural hearing loss.
Results: Five mutations in known hearing loss genes, including 1 nonsense and 4 missense mutations, were identified in
5 different genes (ACTG1, MYO1F, DIAPH1, POU4F3 and EYA4), and the genotypes for these mutations were consistent
with the autosomal dominant inheritance pattern of hearing loss in each family. No mutational hot-spots were revealed
in these Korean families.
Conclusion: Targeted NGS allowed for the detection of pathogenic mutations in affected individuals who were not
candidates for classical genetic studies. This report is the first documenting the effective use of an NGS technique to
detect pathogenic mutations that underlie hearing loss in an East Asian population. Using this NGS technique to
establish a database of common mutations in Korean patients with hearing loss and further data accumulation will
contribute to the early diagnosis and fundamental therapies for hereditary hearing loss.
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A number of hereditary disorders that follow a Mendelian
inheritance pattern are genetically heterogeneous. Heredi-
tary hearing loss is one such heterogeneous disorder, and it
may be caused by a multitude of genes. Currently, muta-
tions in 63 genes have been found to be associated with
hearing loss. However, there are 54 candidate chromosomal
loci at which causative genes have not yet been identified,
although classical genetic studies such as linkage analysis
have predicted that these loci contain novel hearing loss-* Correspondence: kimuk@knu.ac.kr; kylee@knu.ac.kr
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reproduction in any medium, provided the orassociated genes (Hereditary Hearing loss Homepage,
http://hereditaryhearingloss.org). Due to the limitation of
the Sanger sequencing method, which is highly expensive
and time-consuming, it has been difficult to sequence the
hundreds of genes in these candidate chromosomal loci.
Therefore, it has been nearly impossible to identify the pre-
cise pathogenic mutations in affected individuals from
small families who cannot be examined either through
linkage analysis or standard capillary sequencing analysis.
Next-generation sequencing (NGS) can overcome these
limitations through its ability to perform parallel sequen-
cing of billions of nucleotides at a low cost and high speed
[1-4]. The capacity to simultaneously screen thousands
of target genes makes this technique an especially
powerful tool for detecting pathogenic mutations thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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loss. In 2010, Walsh et al. performed whole-exome sequen-
cing in a Palestinian family with hereditary hearing loss and
identified a novel mutation in the gene, GPSM2, which had
been hidden in the autosomal recessive hearing loss locus
(DFNB32) first identified by Masmoudi et al. in 2003 [5].
However, there have been no reports of the detection of
pathogenic mutations by screening candidate hearing loss
genes in small families without using linkage analysis.
Therefore, based on the hypothesis that causative
mutations of hearing loss are more likely to exist in
known hearing loss associated-genes than in novel
genes, we performed exon capture and resequencing
using Illumina library generation and Solexa sequencing
methods.
Subjects and methods
Families and clinical evaluation
Eight small Korean families with hereditary hearing loss were
recruited from the Department of Otorhinolaryngology-
Head and Neck Surgery at the Kyungpook National
University Hospital in Daegu, South Korea (Figure 1).
A total of 31 individuals, including 18 affected and
13 unaffected members, participated in this study. A
clinical questionnaire excluded any history of other
diseases and environmental factors, including infec-
tion, ototoxicity and noise. Physical examinations
ruled out the probability of syndromic hearing loss.
The hearing level in all of the participants was evalu-
ated by audiological tests, including pure-tone audi-
ometry (PTA) and auditory brainstem response
(ABR). PTA was calculated as an average of theFigure 1 Pedigree diagrams of 8 Korean families with autosomal dom
symbol indicates an individual whose genomic DNA was analyzed by targe
in the targeted sequencing and the phenotype of hearing loss was confirm
bar. Squares and circles represent males and females, respectively. Filled sy
individuals.threshold measured at 0.5, 1.0, 2.0 and 4.0 KHz [6],
and air-conduction threshold measurements were
performed at 125-8000 Hz. The level of hearing loss
is described as follows depending on PTA: normal
hearing, below 20 dB; mild hearing impairment, 21
to 40 dB; moderate hearing impairment, 41 to 70 dB;
severe hearing impairment, 71 to 95 dB; and pro-
found hearing impairment, above 95 dB. In addition,
bone conduction thresholds were measured at 250-
4000 Hz to check conductive hearing loss in affected
individuals. One hundred unrelated Koreans with
normal hearing were recruited from Kyungpook Na-
tional University Hospital as normal controls. All of
the participants provided written informed consent
before the study according to the protocol approved
by the Ethics Committee of Kyungpook National
University Hospital. Genomic DNA from 31 indivi-
duals, including 18 patients from 8 families and 100
normal controls, was extracted from peripheral blood or
buccal cells using either the FlexiGene DNA extraction kit
(QIAGEN, Hilden, Germany) or the Puregene Buccal Cell
Core kit, respectively (QIAGEN, Hilden, Germany). All of
the subjects were examined for the GJB2 and the SLC26A4
gene by Sanger sequencing and were negative for both of
the genes.
Targeted resequencing and variation analysis
Using previously published literature, we selected 80
genes that are associated with sensorineural hearing loss
as the target genes for sequencing (Additional file 1:
Table S1). Five microgram of genomic DNA was frag-
mented to approximately 250 base pairs, which wasinant hearing loss. An asterisk in the upper right corner of the
ted sequencing. Co-segregation of the candidate variations detected
ed via Sanger sequencing of DNA from the individuals marked by a
mbols represent affected individuals, and slashes indicate deceased
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for library generation using an Illumina sample prepar-
ation kit (Illumina, Inc., San Diego, CA, USA). All
protein-coding regions and exon-intron boundaries of
the target genes were captured by hybridization with
designed nucleotide probes. The captured target DNA
fragments were sequenced using the Illumina HiSeq
2000 paired-end read sequencing system for 90 cycles
per fragment.
All bioinformatics processing and data analysis, includ-
ing genome alignment, variation detection, filtering and
visualization, were performed on the DNAnexus plat-
form (DNAnexus, Inc., Mountain View, USA, http://
www.dnanexus.com). The millions of reads that were
derived from the targeted sequencing were aligned to the
human reference genome hg19 (University of California,
Santa Cruz). dbSNP Build 134 was used as a reference
for recorded SNPs. The 1000 genome database (http://
www.1000genomes.org) and the Washington University
exome database (http://evs.gs.wathington.edu) were used
as references to investigate the novelty and probable
pathogenicity of the allelic variations detected in our se-
quencing approach. The reliability of variations was esti-
mated by the allele frequency and Ref score, which
represents the PHRED-encoded probability (quality
score) [7,8]. For a probability p, the PHRED-encoded
quality score Q is given by the formula Q= -10log10p.
Variations with a quality score of less than 20 were
regarded as sequencing errors and discarded, and only
alleles that appeared in more than 20% of heterozygotes
from 8 DNFA families were recognized as potentially real
allelic variations. To analyze the possible functional
pathogenic effects of the variants, 2 types of prediction
programs, SIFT (http://sift.jcvi.org) and Mutation taster
(http://www.mutationtaster.org), were used.
Sanger sequencing
Specific exons containing candidate variations were
amplified by polymerase chain reaction (PCR) using
primer sets designed via Primer3 software (http://
www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.
cgi). Each variation was sequenced by the Sanger se-
quencing method using an ABI PRISM Big Dye Ter-
minator Cycle Sequencing Kit v3.1 and an ABI 3130xl
DNA sequencer (Applied Biosystems Corps., Foster
City, CA, USA). Finally, the accurate genotype of the
variations was confirmed by sequence analysis with
the Sequencing Analysis software v5.2 (Applied Biosys-
tems Corps., Foster City, CA, USA) in both the family
members and 100 unrelated normal controls. To investi-
gate the significance of the variations, the conservation
level of amino acids between other species was esti-
mated using a PhyloP score obtained from the UCSC
genome browser (http://genome.ucsc.deu).Results
Clinical features of the 8 Korean families
All 8 families exhibited a typical autosomal dominant in-
heritance pattern of hearing loss (Figure 1). Audiological
assessments of the affected individuals revealed symmet-
rical, bilateral, progressive, sensorineural hearing loss
that affected both genders (Additional file 2: Figure S1).
Patient II-3 of KNUF60 showed asymmetric features
(Table 1). According to PTA tests, the severity of hearing
loss varied among affected individuals, ranging from
mild to profound. The audiogram patterns from all of
the patients were distinct, even between members of the
same family. None of the affected individuals displayed
symptoms of tinnitus, vestibular dysfunction or other
clinical abnormalities indicating syndromic hearing loss.
Targeted resequencing and variation analysis
One (KNUF21) or two members per family were
selected for targeted sequencing (Figure 1). For these
15 individuals, including 13 patients and 2 normal
individuals, we screened 80 candidate deafness genes,
including 46 reported hearing loss genes (Additional
file 1: Table S1). Target enrichment and massively
parallel sequencing using the Illumina HiSeq 2000
paired-end sequencing system produced hundreds of
thousands of target mapped reads (tens of millions of
bases) with an average length of 90 bases. This se-
quencing covered more than 90% of the target
regions with a mean depth ranging from 43× to
337×. More than 78% of the target regions were cov-
ered by 10 or more reads, demonstrating the high
quality of the sequencing (Table 2).
After heterozygous variations were sorted according to
the inheritance patterns of each family, quality control fil-
tering was performed based on the PHRED score ( > 20)
and variant allele frequency (higher than 20%). This
process left hundreds of variations, ranging from 285 to
701 variations per individual (Additional file 3: Table S2).
To identify the most probable pathogenic mutations, we
applied a prioritization scheme, as described in previous
studies [9-11]. First, only heterozygous variants were
selected as candidates based on the autosomal dominant
inheritance pattern of hearing loss in the families. Next,
intergenic or intronic variants were discarded, and only
non-synonymous variants in coding sequences and splice-
site variants were sorted out as probable pathogenic var-
iants, based on their direct association with the protein ex-
pression or function. Because a number of pathogenic
mutations have been registered as dbSNPs in international
biological databases, all previously reported coding
SNPs were ruled out by confirming their allele fre-
quency in several populations and non-pathogenic
properties in the NCBI database (National Center for
Biotechnology Information, http://www.ncbi.nlm.nih.











KNUF21 III-1* Female 1 90 80 - Severe
KNUF24 II-5 Female 44 39 45 Reverse U-shaped Moderate
KNUF26 III-1 Female 18 64 65 Sloping Moderate-severe
KNUF29 II-1 Male 63 54 54 Sloping Moderate
KNUF34 II-5 Male 66 56 53 Sloping Moderate
III-3 Female 21 54 49 Flat Moderate
KNUF46 II-2 Female 35 99 98 Sloping Profound
III-1 Female 9 43 38 Ascending Mild
III-2 Male 7 53 53 Ascending Moderate
III-3 Male 5 63 68 Ascending Moderate-severe
KNUF57 III-1 Female 28 84 89 Ski sloping Severe
III-2 Male 27 54 45 Flat Moderate
KNUF60 II-3 Female 33 91 65 Flat Severe
* The hearing test for III-1 (KNUF21) was performed by auditory brainstem response (ABR).
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This approach yielded an average of 12 novel non-
synonymous variations located in coding regions in
each individual (Additional file 3: Table S2). Most of
these novel non-synonymous variations were mis-
sense or nonsense mutations caused by single nu-
cleotide substitutions, and a few variations were
frame-shift insertions or deletions of a single nucleotide.
These variations were checked for co-segregation with
hearing loss in the two family members who had been
subjected to targeted sequencing, and 10 variations satis-
fied this criterion.Table 2 Run statistics and target coverage of NGS in each ind




KNUF21 III -1 11,555,406 193,3
KNUF24 II -2 54,927,039 201,3
II-5 16,525,672 196,0
KNUF26 II-3 67,166,957 202,4
III-1 9,251,859 192,8
KNUF29 II-1 12,384,809 195,1
III-1 44,392,335 201,1
KNUF34 II-5 57,045,380 201,9
III-3 10,551,804 194,5
KNUF46 II-2 72,336,591 201,6
III-1 14,635,372 195,6
KNUF57 II-2 51,755,311 200,7
III-1 12,911,952 194,4
KNUF60 I-1 59,181,391 202,2
II-3 10,591,967 194,6Identification of candidate mutations of hearing loss in
each family
Variant filtering was performed to identify the most
probable causative variants, and 10 non-synonymous
variants were found to be significant candidates in 7
families, with the exception of the KNUF26 family. A
second co-segregation analysis was performed using the
Sanger sequencing method in 14 additional individuals
(underlined in Figure 1) from the 7 families, and 3 varia-
tions that were not co-inherited with hearing loss were
subsequently ruled out from the candidate mutations.








37 90.05 54 82.22
47 93.78 256 92.21
24 91.30 77 85.82
56 94.30 313 92.41
54 89.83 43 78.26
04 90.87 58 83.71
09 93.67 207 92.14
06 94.04 263 92.39
36 90.61 50 82.51
93 93.94 337 92.55
93 91.15 68 83.51
56 93.51 241 92.20
67 90.58 60 84.60
84 94.22 276 92.47
15 90.65 49 82.61
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Although all of these variations were found in genes pre-
viously known to be associated with hearing loss, 5 of
the 7 variations were novel missense (p.D187H in
ACTG1, p.P678S in DIAPH1, p.E232K in POU4F3 and p.
P1422L in COL11A2) or nonsense mutations (p.S288X
in EYA4) that had not been recorded in any public data-
bases [12-18]. Sanger sequencing confirmed that all 7
variations in the 7 DFNA families were heterozygous in
the patients with hearing loss, which was consistent with
the inheritance pattern of the disorder.
To estimate the probable pathogenicity of the variants,
evolutionary conservation and the predicted damaging
effects of the amino acid substitution were analyzed. In
most of the variants, the amino acid where the substitu-
tion occurred was highly conserved in a number of ver-
tebrates showing positive PhyloP scores (Figure 2). In
addition, two prediction programs, Mutation Taster and
SIFT, strongly predicted that the variants would inter-
rupt normal protein function (Table 3). However, one
variant, proline at position 1422 in the COL11A2 gene,
was not conserved between other species and was pre-
dicted to be a probable polymorphism using Mutation
Taster. Control sequencing of 100 unrelated normal
individuals practically supported these predictions. How-
ever, we excluded two variants, the p.E737K variant in
WFS1 and the p.P1422L variant in COL11A2 from the
candidate mutations, because these two variants were
detected in 5 and 2 normal controls, respectively
(Table 3). In addition, p.E737K in WFS1 was also
detected in normal European American population
(rs147834269) in the Washington University exome
database (http://evs.gs.wathington.edu). Furthermore, it












KNUF21 ACTG1 4 Missense c.559G>C p.D187H 2.
KNUF24 EYA4 11 Nonsense c.863 C>A p.S288X 2.
KNUF29 MYO1F 14 Missense c.1504 A>G p.I502V 1.
KNUF34 WFS1 8 Missense c.2209G>A p.E737K 2.
KNUF46 DIAPH1 16 Missense c.2032 C>T p.P678S 1.
KNUF57 POU4F3 2 Missense c.694G>A p.E232K 2.
KNUF60 COL11A2 59 Missense c.4265 C>T p.P1422L 1.
* p.E737K in WFS1 and p.P1422L in COL11A2 found in normal controls were elimina
The p.S288X variant in EYA4 was not predicted by SIFT because it is a nonsense var
†DC, disease causing; PO, polymorphism. { score ranges from 0, damaging to 1, neuin several studies that provided strong evidence that this
variant was not the genetic cause of hearing loss in the
KNUF34 family [19,20]. In contrast, the other 5 variations
(p.D187H in ACTG1, p.S288X in EYA4, p.I502V inMYO1F,
p.P678S in DIAPH1 and p.E232K in POU4F3) were ab-
sent in all 100 normal controls in this study. In addition,
none of the healthy controls in the 1000 genomes project
and the Washington University exome database carried
these variants, suggesting that they could be pathogenic
mutations.
The p.D187H variation in ACTG1 was detected in pa-
tient III-1 of the KNUF21 family and followed an auto-
somal dominant inheritance pattern (Figure 2a). This
variation was observed in 17 of 39 reads (44%) and had
a quality score of 35, indicating heterozygosity. Genotype
confirmation using Sanger sequencing revealed that two
patients, II-2 and III-1, were heterozygous for this muta-
tion. A normal individual, II-1, was homozygous for the
wild type, consistent with the autosomal dominant in-
heritance pattern of the disorder.
The p.S288X mutation in EYA4 was identified in the
KNUF24 family (Figure 2b). In the targeted sequencing,
the p.S288X mutation appeared in 45% of reads (21 of 47)
and had a variation score of 35, indicating heterozygosity.
Sanger sequencing revealed that this mutation is co-
segregated with hearing loss in one patient (II-5) and was
absent from two unaffected members (II-2 and III-2).
The KNUF29 family had dominant hearing loss that was
confirmed to be caused by the p.I502V mutation in
MYO1F (Figure 2c). The heterozygosity and reliability of
this mutation was supported by a 35% variation frequency
(17 of 46) and a variation score of 35. This result was con-
firmed by Sanger sequencing, and only patient II-1 had the












85 DC - 0.00 Novel
47 DC Tolerated
/ 0.50
0.00 Zadro et al., 2009
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/ 0.15











ted from the final candidate mutations.
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tral.
Figure 2 The identification of 5 non-synonymous variations showing co-segregation with hearing loss in affected families. Top:
Visualization of individual sequencing reads covering the mutations in the genes. The actual read depth for these mutated nucleotides ranged
between 46× and 442×. Blue and green reads represent the positive and negative strands, respectively, and the red bases represent bases that
differ from the reference sequence (black). Middle: Verification of each variation by Sanger sequencing. All 5 of the variations marked by black
arrows are single nucleotide substitutions leading to early truncation of the polypeptide or a change in the amino acid. Bottom: A comparison
of amino acid sequences of each gene in multiple vertebrate species. The asterisks indicate the amino acid substituted by the mutation. A single
line between the aligned amino acids indicates that there is no base in the aligned species, and a double line indicates that the aligned species
has one or more bases that cannot be aligned in the gap region. The majority of the mutated amino acids are strongly conserved across the 9
different species shown.
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syndromic hearing loss (Additional file 2: Figure S1).
This type of hearing loss is uncommon and has been
associated with only the DIAPH1, MYO7A and WFS1
genes [21]. Interestingly, we identified the missense mu-
tation, p.P678S of DIAPH1 in this family (Figure 2d),
and it showed coincident audiographical configuration
with known DFNA1 (DIAPH1) hearing loss. This mis-
sense mutation was observed in 53 of 121 reads, with a
variation score of 40. Site-directed sequencing confirmed
that only the hearing loss patients in this family (of 4
patients and 2 controls sequenced) were heterozygous
for the mutation.
A novel missense mutation, p.E232K in POU4F3,
was identified in the KNUF57 family (Figure 2e).
Thirty-six percent of all reads had this mutation, with
a variation score of 35 in the targeted sequencing. Five
family members, including 4 patients, were sequenced
for the mutation by Sanger sequencing, which verified
co-segregation.
In summary, the targeted sequencing of 15 individuals
from 8 DFNA families yielded 10 candidate non-
synonymous mutations as the primary causes of hearing
loss. Sanger sequencing was carried out in 31 indivi-
duals, including 16 additional family members, to con-
firm whether these 10 variations are co-segregated with
hearing loss. This sequencing allowed us to confirm the7 co-inherited variations. Finally, variation screening in
100 normal controls using Sanger sequencing confirmed
5 variations as probable pathogenic mutations in 5 of
the families.
Discussion
The purpose of this study was to identify the genetic
basis of hereditary hearing loss using next-generation se-
quencing technology in small families who could not be
analyzed using the current genetic approaches. Eight
small families with autosomal dominant, non-syndromic,
sensorineural hearing loss were selected, and 80 target
genes associated with hearing loss were screened using
target capture and massively parallel sequencing meth-
ods. In current study, 5 non-synonymous mutations
were confirmed in 5 of the 8 families. The causative
genes underlying the hearing loss in the 3 other families
are still awaiting discovery. There are 2 possible explana-
tions for the hearing loss in these families: (1) patho-
genic mutations exist in 1 of the 80 candidate genes
studied but in an exon that was not covered by our se-
quencing (approximately 6-10%) or within intronic regu-
latory sequences, (2) their causative mutation is in an
as-yet-unidentified hearing loss gene. However, 5 distinct
causative mutations were identified in the other 5 fam-
ilies, including 4 missense mutations and 1 nonsense
mutation. None of these mutations, except the p.I502V
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studies of hereditary hearing loss.
ACTG1 (NM_001199954), which is responsible for
DFNA20/26 hearing loss, encodes γ-actin, one of the
non-muscle cytoskeletal proteins. This protein is pre-
dominantly expressed in cochlear hair cells and contri-
butes to the structural maintenance of stereocilia,
cuticular plates and adherens junctions [22]. γ-actin con-
sists of 4 sub-domains (sub-domains 1-4), and the novel
missense mutation p.D187H that is caused by a
c.559 G>C transversion results in the substitution of a
basic amino acid (histidine) for an acidic amino acid
(aspartic acid) in sub-domain 4. Otterbein et al. found
that even minor changes in this domain may lead to
major effects on the structural stability of the actin poly-
mer [23]. Using 2D gel electrophoresis, Verrills et al.
identified that p.D187H in ACTG1 leads to the expres-
sion of more basic gamma-actin in leukemia cells, and
they reported that Asp187 is a surface residue in close
proximity to the ATP-binding cleft of the protein. The
substitution of the histidine for aspartic acid in ACTG1
changes the charge from negative to positive, which
results in reduced hydrophobicity and electrostatic inter-
actions in this region. According to their research, mu-
tant gamma-actin expressing leukemia cells display
resistance to anti-microtubule drugs. The mutant
gamma-actin expressing cells intactly retained their
morphology, whereas the cells expressing wild-type
gamma-actin were contracted and destroyed. These data
suggest that the Asp187 residue in gamma-actin contri-
butes to the interaction with microtubules, and the
p.D187H variant inhibits depolymerization of tubulin in
leukemia cells. This result suggests that the p.D187H vari-
ant could collapse the polymerization-depolymerization
balance of microtubules, which leads to the destruction of
cellular homeostasis in normal hair cells [24]. These con-
clusions from previous biochemical studies provide con-
vincing evidence that p.D187H is a novel mutation that
has pathogenic effects on the normal functions of γ-actin
in the hair cells.
Mutation p.S288X in EYA4 (NM_004100.4) was the
only nonsense mutation identified in this study. The
protein encoded by EYA4 (DFNA10) is a member of the
vertebrate Eya family of transcriptional activators, and it
consists of two functional domains: the C-terminal EYA
homolog domain and the N-terminal transactivation do-
main [13]. The EYA homolog domain and SIX family
transcription factors interact to form transcriptional
complexes that regulate the expression of target genes
that are required for the development and maturation
of the organ of Corti [13]. Most of the reported
EYA4 mutations produce truncated proteins missing a
part of the EYA homolog domain [25]. The novel
nonsense mutation p.S288X changed Ser288 to a stopcodon, which produced a truncated protein lacking
the entire EYA homolog domain. It suggests that this
nonsense mutation may inhibit normal development
and maintenance of the organ of Corti and cause sen-
sorineural hearing loss.
MYO1F (NM_012335.3) has been frequently proposed
as a candidate hearing loss gene, because several myosin
genes have been demonstrated as causative genes of
non-syndromic hearing loss and MYO1F is expressed in
cochlea. Recently, Zadro et al. reported that MYO1F
mutations were identified in hearing loss patients, and
one of the reported mutations, p.I502V, was detected in
this study [14]. According to their study, the mutated
residue, Ile502, is located near the actin-binding site in
the motor domain of myosin-1 f. Through homology
modeling, it was predicted that the Ile502 residue contri-
butes to the structural stabilization of the protein by
forming hydrophobic interactions with the Val444,
Leu447 and Ile448 residues. Additionally, there is an
ATP-binding site near Ile502. Therefore, the authors
concluded that the substitution of isoleucine for valine
may interrupt the hydrophobic interaction with other
residues, resulting in structural instability of the protein
and disturbance of ATP binding. Based on these predic-
tions, it can be hypothesized that the p.I502V mutation
likely has a pathogenic effect on the cellular function of
myosin-1 F [14].
Human diaphanous 1 protein, encoded by DIAPH1
(NM_005219.4), belongs to the formin protein family,
which regulates various cellular mechanisms such as
cytoskeleton remodeling and the maintenance of cell po-
larity in hair cells [16,26-29]. The formins have several
functional domains, including formin homology-1 and 2
domains (FH1, FH2), which play a key role in the
polymerization of unbranched actin filaments by inter-
acting with profilin [26,30,31]. The FH1 domain is char-
acterized by consecutive proline residues. Profilin-actin
complexes bind to the poly-L-proline stretch of the FH1
domain and are assembled into unbranched actin fila-
ments allowing barbed end elongation [32]. The novel
mutation p.P678S is located in the poly-L-proline stretch
of the FH1 domain. This mutation changes a hydropho-
bic non-polar residue (proline) to a hydrophilic polar
residue (serine) in the poly-L-proline stretch, and it will
likely adversely affect actin polymerization at the barbed
end. Therefore, it can be hypothesized that this mutation
may disturb the interactions with partner proteins,
which interrupts actin polymerization and collapses cel-
lular polarity in hair cells of cochlea.
Transcription factors bind directly to DNA and regu-
late expression of target genes. Brn-3.1, encoded by the
POU4F3 gene (NM_002700.2), is a well-known tran-
scription factor that contributes to the differentiation
and survival of hair cells in cochlea [33,34]. This protein
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POU-specific domain and a POU-homeodomain. In the
DNA binding domains, the molecular features of amino
acids such as electric property and acidity significantly
influence the maintenance of the structural conform-
ation of the protein [34,35]. The p.E232K mutation
detected in this study is caused by a single nucleotide
substitution of adenine for guanine at nucleotide pos-
ition 694, resulting in the replacement of a negatively
charged glutamic acid with a positively charged lysine in
an α-helix (α3) in the POU-specific domain. According
to 3D modeling by Collin et al., among the 4 α-helix
structures in the POU-specific domain, the α3 helix
where the variant p.E232K occurs has the most direct
interaction with target DNA [34]. Thus, altered electric
properties of the Glu232 residue would directly reduce
the structural stability of the domain or the strength of
the interaction with the target DNA. It suggests that this
missense mutation might have pathogenic effects on the
maturation and survival of hair cells by failing to regu-
late the expression of downstream genes.
Although the pedigrees have insufficient genetic infor-
mation, various probable pathogenic mutations were
successfully detected by NGS technique and molecular
genetic analysis in current study. Moreover, it will com-
pletely overcome the weakness of this study ensuring
pathogenicity of the mutations when segregation study
for the detected mutations can be performed with all of
the members in the family.
According to a number of previous genetic studies, her-
editary hearing loss shows distinct spectrums and preva-
lence of mutations in different ethnic groups [36-40]. For
example, the GJB2 gene accounts for approximately
20-40% of genetic hearing loss in Caucasian popula-
tions but only 10% of genetic hearing loss in Korean
populations [37,38,41-43]. In addition, the most fre-
quent GJB2 mutation also varies among populations:
c.35delG, c.235delC and c.167delT are the most com-
mon variants in Caucasian, Asian and Jewish popula-
tions, respectively [38,44-46]. However, this feature
may not be applicable for autosomal dominant hear-
ing loss because major hearing loss genes such as
GJB2 and SLC26A4 predominantly cause autosomal
recessive hearing loss. To date, no major genes have
been described that cause a significant proportion of
dominant hearing loss in any ethnic population. In
this study, 5 mutations were detected in 5 different
genes in 5 Korean families with autosomal dominant,
non-syndromic, sensorineural hearing loss. Addition-
ally, we provide the first evidence of pathogenic muta-
tions in the ACTG1, EYA4, DIAPH1 and MYO1F genes in
a Korean population. These results, as well as previous
genetic studies performed by our group, suggest that there
are no mutational hot spots for dominant hearing loss inthe Korean population [33,47-50]. This conclusion is con-
sistent with the idea that the genetic causes of autosomal
dominant hearing loss are more heterogeneous than those
of autosomal recessive hearing loss in most ethnic groups.
Because of these characteristics, it is difficult to diag-
nose and establish the exact causes of hereditary hearing
loss, although it accounts for approximately 50% of all
hearing loss [51]. Currently, several simple DNA tests
are performed in medical institutions in many countries
to diagnose hereditary hearing loss. However, the test
evaluates only few major genes, such as GJB2, SLC26A4
and mitochondrial genes, and is unable to detect other
genetic causes of hereditary hearing loss. Considering
that the ultimate goal of genetic disease research is to
establish basic information and genetic databases for
clinical diagnosis and treatment, the use of population
genetic studies to accurately understand the genetic
background of diseases is essential. Although current
genetic technologies, such as linkage analysis and Sanger
sequencing, are very reliable methods for identifying
genomic variations associated with genetic disorders,
they are not well suited for the analysis of heterogeneous
diseases. Next-generation sequencing (NGS) is acceler-
ating the qualitative improvement of mutational studies
for numerous heterogeneous disorders due to its ability
to perform simultaneous and massively parallel se-
quencing. Although the current NGS technique is too
expensive to be widely used, the cost of NGS is grad-
ually decreasing, which will lead to the increased ap-
plicability of this technology. Two recent population
genetic studies on hereditary hearing loss have been
performed in American and Jewish populations [52,53].
In these studies, various genetic mutations and a
founder mutation were detected using next-generation
sequencing. Our study is the first report of dominant
hearing loss causative gene mutations identified by the
targeted-sequencing of affected individuals in an East
Asian population. Our successful identification of several
pathogenic mutations using target-capture and massively
parallel sequencing demonstrates that gene targeted se-
quencing is a highly effective and powerful tool for clin-
ical and population genetic studies of heterogeneous
disorders.Additional files
Additional file 1: Table S1. Eighty genes targeted for the next-
generation sequencing.
Additional file 2: Figure S1. Audiograms for PTA (pure-tone
audiometry) thresholds of 7 probands (A – G) and a normal family
member (H. KNUF24: III-2). The most of probands except II-3 of KNUF60
(G), show symmetrical bilateral high frequency hearing loss, which is
general audiographical aspect of autosomal dominant non-syndromic
hearing loss. The proband III-1 of KNUF46 who shows low-to-mid
frequency hearing loss, carries a missense mutation (p.P678S) in DIAPH1
Baek et al. Orphanet Journal of Rare Diseases 2012, 7:60 Page 9 of 10
http://www.ojrd.com/content/7/1/60gene which causes low frequency hearing loss. It provides a strong
possibility that p.P678S is the pathogenic mutation causing hereditary
hearing loss in family KNUF46.
Additional file 3: Table S2. Summary of genetic variations detected in
targeted sequencing.
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